Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today development of a novel immunotherapy for treatment of solid tumors. Current cellular approaches to kill cancer involve administration of a specific type of modified T cell called "chimeric antigen receptor" (CAR) T cell.